More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

In updated American recommendations for the management of acute coronary syndrome (ACS), bleeding reduction strategies on antiplatelet therapy are embraced, as are non-statin lipid-lowering therapies ...

The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case Reports in Clinical Medicine, 14, 123-129. doi: 10.4236/crcm.2025.143016 .

De-escalating dual antiplatelet therapy from from aspirin plus ticagrelor to aspirin plus clopidogrel after primary ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its superior antiplatelet potency compared with ...

Common antiplatelet medications include aspirin, which inhibits the enzyme cyclooxygenase-1 (COX-1), and clopidogrel, which blocks the P2Y12 receptor on platelets. By preventing platelets from ...

Singh, A. , Sinha, R. , Saran, M. , Kazmi, D. , Gupta, H. and Seth, G. (2025) Efficacy and Safety of Dual Antiplatelet Therapy in High-Risk, Post-Percutaneous Coronary Intervention Patients beyond One ...

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug ...